

**SUPPLEMENTAL DATA** : List of the 49 articles that entered the literature analysis.

1. Arauz A, Hoyos L, Zenteno M, Mendoza R, Alexanderson E. Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study. *Clin Neurol Neurosurg.* 2007;109:409–412.
2. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. *J Nucl Cardiol.* 2006;13:791–800.
3. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18 F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. *J Nucl Med.* 2004;45:1816–1821.
4. Bucerius J, Duivenvoorden R, Mani V, et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. *JACC Cardiovasc Imaging.* 2011;4:1195–1205.
5. Bucerius J, Mani V, Moncrieff C, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. *J Am Coll Cardiol.* 2012;59:2080–2088.
6. Bural GG, Torigian D, Chamroonrat W, et al. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. *Nucl Med Biol.* 2006;33:1037–1043.
7. Bural GG, Torigian D, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. *Eur J Nucl Med Mol Imaging.* 2008;35:562–569.
8. Calcagno C, Ramachandran S, Izquierdo-Garcia D, et al. The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. *Eur J Nucl Med Mol Imaging.* 2013;40:1884–1893.
9. Choi Y, Youn H, Chung W. Uptake of F-18 FDG and ultrasound analysis of carotid plaque. *J Nucl Cardiol.* 2011;18:267-272.
10. Davies JR, Rudd JHF, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. *Stroke.* 2005;36:2642–2647.

11. Derlin T, Tóth Z, Papp L, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. *J Nucl Med*. 2011;52:1020–1027.
12. Duivenvoorden R, Mani V, Woodward M, et al. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. *JACC Cardiovasc Imaging*. 2013;6:1087–1094.
13. Dunphy MPS, Freiman A, Larson SM, Strauss HW. Association of vascular 18 F-FDG uptake with vascular calcification. 2005;46:1278–1284.
14. Fayad Z, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. *Lancet*. 2011;378:1547–1559.
15. Fifer KM, Qadir S, Subramanian S, et al. Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. *J Am Coll Cardiol*. 2011;57:971–976.
16. Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). *Eur J Vasc Endovasc Surg*. 2009;37:714–721.
17. Izquierdo-Garcia D, Davies JR, Graves MJ, et al. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. *Stroke*. 2009;40:86–93.
18. Jezovnik MK, Zidar N, Lezaic L, Gersak B, Poredos P. Identification of inflamed atherosclerotic lesions in vivo using PET-CT. *Inflammation*. 2013.37:426–434.
19. Joly L, Djaballah W, Koehl G, et al. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification. *Eur J Nucl Med Mol Imaging*. 2009;36:979–985.

20. Kim TN, Kim S, Yang SJ, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. *Circ Cardiovasc Imaging*. 2010;3:142–148.
21. Kwee RM, Truijman MTB, Mess WH, et al. Potential of integrated [18F] fluorodeoxyglucose positron-emission tomography/CT in identifying vulnerable carotid plaques. *AJNR Am J Neuroradiol*. 2011;32:950–954.
22. Kwee RM, Teule GJJ, van Oostenbrugge RJ, et al. Multimodality imaging of carotid artery plaques: 18F-fluoro-2-deoxyglucose positron emission tomography, computed tomography, and magnetic resonance imaging. *Stroke*. 2009;40:3718–3724.
23. Lee SJ, On YK, Lee EJ, Choi JY, Kim B-T, Lee K-H. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. *J Nucl Med*. 2008;49:1277–1282.
24. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. *Ann Neurol*. 2012;71:709–718.
25. Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM. What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. *Atherosclerosis*. 2010;211:136–140.
26. Menezes LJ, Kotze CW, Agu O, et al. Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. *J Nucl Med*. 2011;52:1698–1703.
27. Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. *JACC Cardiovasc Imaging*. 2011;4:1110–1118.
28. Noh TS, Moon S-H, Cho YS, et al. Relation of carotid Artery 18F-FDG uptake to C-Reactive protein and Framingham risk score in a large cohort of asymptomatic adults. *J Nucl Med*. 2013;54:2070–2076.

29. Okane K, Ibaraki M, Toyoshima H, et al. 18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. *Eur J Nucl Med Mol Imaging*. 2006;33:589–594.
30. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. *J Nucl Cardiol*. 2008;15:209–217.
31. Ripa RS, Knudsen A, Hag AMF, Lebech A, Loft A, Sune H. Feasibility of simultaneous PET / MR of the carotid artery : first clinical experience and comparison to PET / CT. *Am J Nucl Med Mol Imaging*. 2013;3:361–371.
32. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. *JACC Cardiovasc Imaging*. 2010;3:388–397.
33. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. *J Nucl Med*. 2009;50:1611–1620.
34. Rudd JHF, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. *J Nucl Med*. 2008;49:871–878.
35. Rudd JHF, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. *Circulation*. 2002;105:2708–2711.
36. Rudd JHF, Myers KS, Bansilal S, et al. The Relationships between regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective FDG PET/CT imaging study. *Circ Cardiovasc Imaging*. 2009;2:107–115.
37. Rudd JHF, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. *J Am Coll Cardiol*. 2007;50:892–896.
38. Silvera S, el Aidi H, Rudd JHF, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. *Atherosclerosis*. 2009;207:139–143.

39. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. *J Am Coll Cardiol*. 2006;48:1825–1831.
40. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. *Eur Heart J*. 2007;28:2243–2248.
41. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. *J Am Coll Cardiol*. 2007;49:1533–1539.
42. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible findings for active atherosclerosis. *Radiology*. 2003:831–837.
43. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. *J Am Coll Cardiol*. 2006;48:1818–1824.
44. Tawakol A, Fayad Z, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. *J Am Coll Cardiol*. 2013;62:909–917.
45. Truijman MTB, Kwee RM, van Hoof RHM, et al. Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. *Stroke*. 2013;44:3568–3570.
46. Wu Y, Kao H, Chen M, Lee B, Tseng WI, Jeng J. Characterization of plaques using 18 F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. *J Nucl Med*. 2007:227–233.
47. Wu Y-W, Kao H-L, Huang C-L, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. *Eur J Nucl Med Mol Imaging*. 2012;39:399–407.

48. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. *J Nucl Med.* 2009;50:563–568.
49. Yoo HJ, Kim S, Park MS, et al. Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: analysis with 18F-FDG PET. *J Nucl Med.* 2011;52:10–17.